Given all of this feasibility, lncRNAs that can activate NF-κB, like CamK-A, could support the inflammatory and metastatic behavior of thyroid tumors and be feasible targets for future therapy [103,104]. This evidence concerns the gene NFKB1 and thyroid tumor.